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The PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis Study (The POSEIDON Study).
Hypothesis and Purpose
As the field of cell-based therapy for heart disease progresses, one of the major challenges and opportunities is the development of allogeneic (allo) therapy. Heretofore, allo MSCs have undergone very limited testing in humans, and no trial has compared allogeneic to autologous (auto) cells. To address these issues, we conducted the POSEIDON trial to test the hypothesis that allo MSCs represent a safe and efficacious alternative to auto MSC therapy.
Study Design and Enrollment
The details of this phase I/II trial are posted on www.clinicaltrials.gov under #NCT01087996, while the protocol is posted on www.sccelltherapy.net. The NHLBI Gene and Cell Therapy Data and Safety Monitoring Board (DSMB) were responsible for safety oversight via real time review of serious adverse events (SAE) and twice yearly meetings. In addition, the DSMB reviewed safety data after 5 patients in each group had been followed for 30 days. The DSMB recommended study continuation at the conclusion of each review period. As a result, 30 patients received the study injection: five patients in each cell type/dose level combination.
Study Procedures and Timeline
For patients randomized to the allo MSC group, the allo stem cell source was manufactured by the University of Miami Interdisciplinary Stem Cell Institute and derived from bone marrow aspirates of healthy donors. Two healthy male individuals between 20 and 35 years old provided informed consent to participate in donation of their bone marrow. They underwent comprehensive history and physical examination, completed the National Marrow Donor Program (NMDP) questionnaire, and were screened for infectious diseases and blood tests ruling out hypercoagualopathies, hematopoietic disorders and other blood abnormalities. MSCs were delivered to 10 sites in an infarcted myocardial territory as described below. Following cardiac catheterization and transendocardial cell injections, patients were hospitalized for a minimum of 4 days, and were followed clinically two weeks post-catheterization, at monthly intervals thereafter for six months for all safety and efficacy assessments, at 12 months for selected efficacy and safety assessments, and at a final 13-month visit for follow-up CT scans of the heart, and of the chest, abdomen, and pelvis. One patient did not undergo the 13-month CT because of renal dysfunction, and two patients were not included in the 13-month CT analysis because of intervening heart transplantation (n=1) or left ventricular assist device (LVAD) implantation (n=1).
Characterization of Allo and Auto MSCs
MSCs were identically prepared from autologous and allogeneic sources as previously described 1 . Briefly, MSCs were isolated from the bone marrow mononuclear cells by plastic adherence and culture expansion. After 4-5 weeks in culture, sufficient quantities of MSCs were available for injection into the patients. Cells met pre-specified release criteria prior to clinical use 1 .
Transendocardial Stem Cell Injection (TESI)
Cell product was delivered to an infarcted left ventricular myocardial territory by transendocardial injection using the Biocardia Helical Infusion Catheter (HIC) through an 8 French deflectable guiding catheter (Morph, Biocardia Inc.) as previously described 2,3 . Patients underwent retrograde left heart catheterization from a femoral artery approach. Well opacified simultaneous biplane left ventriculography was performed, typically with at least 60 cc of contrast, in two orthogonal projections to delineate the anterior, apical, inferior, septal, and posterior segments. Diastolic endocardial contours were traced onto a clear plastic overlay sheet. Target segments were identified by correlating areas of myocardial akinesis and hypokinesis with clinical and study imaging data. Unfractionated heparin was given to achieve an activated coagulation time (ACT) >250s. The Morph catheter was used for navigation within the chamber, and the HIC used to engage and inject cell suspension product into 10 sites encompassing an infarct territory. Monitoring for myocardial perforation and pericardial tamponade was with transthoracic echocardiography immediate before, immediately after, 4 hours after, and 24 hours after TESI.
Cardiac Computed Tomography (CT)
Cine-angiographic multidetector row computed tomography (cine-MDCT) was performed in all patients at screening and at the 13-month follow-up visit. Cardiac MDCT provided global LV function and volume, sphericity index 4-6 , and early enhancement defects (EED) 7,8 . LV sphericity index was LDEDV / ( LVLd 3 /6) according to Lamas et al 6 . Imaging was performed using 128 slice (Siemens AS+, Siemens Medical Solutions) or 356-slice (Toshiba) CT scanning systems on supine patients during continuous ECG monitoring; beta-blockers were not administered to slow the heart rate prior to the exam. After scout imaging, radiographic contrast (140 ml) was given, and LV function assessment was performed with a temporal resolution of 100-150 msec. Dose modulation and low tube voltage (100 kV) were used to minimize radiation. Cine-MDCT acquisitions were reconstructed from the immediate post-injection scan between 0-95% of the R-R interval at 5% increments, and analyzed using iNtuition ver.4.4.7.47 (TeraRecon, Inc., Foster City, Calif., USA) to determine global LV systolic function, end-systolic and end-diastolic volumes, LV stroke volume, wall thickness, wall thickening and LV remodeling parameters. A semi-automated method was used with manual contour corrections when necessary.
Multidetector CT and Interpretation of Early Enhancement Defects
Reformation, processing, and assessment of the presence and characteristics of early enhancement defects (EED) on the early MDCT scan were performed by a trained research fellow (V.S.) and validated by an attending radiologist (E.G. or J.F, each with 10 year experience in cardiac CT) using iNtuition ver.4.4.7.47, (TeraRecon, Inc., Foster City, Calif., USA). Contiguous 8 mm thick short-axis reformations were reconstructed for the end diastolic and end systolic cardiac phases as well as a mid diastolic phase (usually 70% of the R-R interval) encompassing the entire left ventricular myocardial volume. Each short-axis section (4 slices at base, 4 slices at mid, and distal 3-4 slices at apical LV regions) was divided into either six (base and mid LV regions) or four (apical LV region) according to the American Heart Association 17-segment model 9 , omitting the most apical segment. Normal reference CT Hounsfield unit (HU) myocardial density numbers were obtained from regions of interest of approximately 10-15 mm 2 in a myocardial segment that demonstrated normal regional function, i.e. normal myocardial wall motion and thickening. For optimal evaluation of EED the CT window level was adjusted so that the center of the scale corresponded to 20 HU below the normal myocardial reference value 7,8 . This approach was chosen to define a visual threshold of approximately 2 standard deviations below the mean of normal myocardium enhancement, allowing optimal conspicuity of hypoenhancement. A narrow window width was used (100-150 HU) to emphasize the threshold between normal and abnormal myocardium and still allow the surrounding anatomy to be visualized. EED were identified by their crescentic shape, subendocardial and/or transmural location, and presence on at least two of the three examined cardiac phases. Hypoattenuating artifacts resulting from cardiac motion and AICD leads were omitted from the analysis. These artifacts were identified by their linear shape, mid-or subepicardial location, transient or migratory location between cardiac phases and by their anatomic proximity to AICD leads. Typically these artifacts tended to affect the inferior septum and inferior wall segments in subjects with right ventricular AICD leads and included the lateral wall segments in cases with biventricular AICD leads. Using the cardiac phase on which hypoattenuating artifacts were minimal and true EED was best defined, EED were digitally traced to obtain measurements for defect area per segment and mean Hounsfield units. Total EED mass per patient was calculated by summing all segmental defect areas and multiplying the total by section thickness (0.8 cm) and then by 1.05 g/cm 3 (myocardial specific gravity) 7 .
Chest / Abdomen / Pelvic CT Chest, abdominal, and pelvic CT with oral contrast was screened for ectopic tissue formation by standard clinical protocol following the cardiac function and rest perfusion scans.
Immunologic Monitoring
Serum samples were collected at four times: pre-infusion and 24 hours, 1 and 6 months post-infusion. Participant anti-HLA alloantibody sensitization status was determined using One Lambda LABScreen® assays (One Lambda, Inc., Canoga Park, CA). Donor HLA typing was performed using One Lambda LABType® assays (One Lambda, Inc., Canoga Park, CA) for HLA A, B, C, DRB1, DQB1 and DRB3,4,5. Patient serum was mixed with microbeads coated with HLA antigen mixtures (LABScreen Mixed screening assay) or purified Class l or Class II HLA antigens and read using a Luminex array analyzer. Any patients indicating sensitization were subsequently tested using LABScreen® Single Antigen assay (One Lambda, Inc., Canoga Park, CA) to determine specificities of the anti-HLA antibodies. Patient serum demonstrating antibodies to donor antigens was cross-matched with donor T and B cells using 3-color flow cytometry as described 10 .
Statistical Analysis
The study was designed to estimate the confidence interval of TE-SAE at 30-days post-TESI among both the allo and auto MSC groups. The underlying rate of 30-day TE-SAE was assumed to be 25% across all three-dose levels, (i.e., SAEs in 3 or 4 patients out of 15). In this setting, the exact binomial 95% confidence interval is 0.04-0.48. Rates of TE-SAEs, AEs, and SAEs were compared using Fisher's Exact Test at 30 days and 12 months. For continuous measures, normality of data was tested using the Shapiro-Wilk Test. If normality was established, differences between groups were tested by Student's t-test and changes from baseline by the paired t-test. If normality could not be established, the Mann-Whitney U Test and the non-parametric Wilcoxon test were used. For evaluation of normally distributed efficacy parameters, we employed a repeated measures analysis of variance (ANOVA) model using the entire data set that included between group (allogeneic vs. autologous) comparisons as well as time and group*time interaction term. Bonferonni correction was applied in post-hoc analyses. A p-value <0.05 was considered statistically significant. All p-values displayed are two-sided. Analyses were conducted using the SAS System, version 9.2 (Cary, NC). All analyses conformed to the pre-specified objectives of the trial. 1 (6.7%) 0 (0.0%) Angina unstable 0 (0.0%) 1 (6.7%) Atrial fibrillation 2 (13.3%) 0 (0.0%) Cardiac failure 3 (20.0%) 4 (26.7%) Mitral valve incompetence 1 (6.7%) 0 (0.0%) Myocardial infarction 1 (6.7%) 0 (0.0%) Palpitations 1 (6.7%) 1 (6.7%) Ventricular tachycardia 1 (6.7%) 5 (33.3%) Eye disorders 1 (6.7%) 0 (0.0%) Gastrointestinal disorders 1 (6.7%) 3 (20.0%) General disorders and administration site conditions 1 (6.7%) 2 (13.3%)
Infections and infestations 3 (20.0%) 2 (13.3%) Injury, poisoning and procedural complications 2 (13.3%) 0 (0.0%) Metabolism and nutrition disorders 2 (13.3%) 0 (0.0%) Musculoskeletal and connective tissue disorders 0 (0.0%) 2 (13.3%)
Nervous system disorders 0 (0.0%) 4 (26.7%) Renal and urinary disorders 0 (0.0%) 1 (6.7%) Respiratory, thoracic and mediastinal disorders 2 (13.3%) 1 (6.7%) Skin and subcutaneous tissue disorders 0 (0.0%) 1 (6.7%) Vascular disorders 2 (13.3%) 1 (6.7%) Subjects with at least 1 SAE 5 (33.3%) 8 (53.3%) Cardiac disorders 3 (20.0%) 7 (46.7%) Cardiac failure 2 (13.3%) 4 (26.7%) Myocardial infarction 1 (6.7%) 0 (0.0%) Ventricular tachycardia 0 (0.0%) 4 (26.7%) Gastrointestinal disorders 1 (6.7%) 1 (6.7%) Infections and infestations 1 (6.7%) 0 (0.0%) Nervous system disorders 0 (0.0%) 1 (6.7%) Renal and urinary disorders 0 (0.0%) 1 (6.7%) Respiratory, thoracic and mediastinal disorders 1 (6.7%) 1 (6.7%) Surgical and Medical Procedures 0 (0.0%) 1 (6.7%) Vascular disorders 1 (6.7%) 0 (0.0%) MACE 3 (20.0%) 4 (26.7%) Deaths 0 (0.0%) 0 (0.0%) Ectopic Tissue Formation 0 (0.0%) 0 (0.0%)
Values are presented as n or n (%); AE=Adverse Event, SAE=Serious Adverse Event, MACE=Major Adverse Cardiac Event (defined as the composite incidence of (1) death, (2) hospitalization for worsening HF, or (3) 
